



## SCIENTIFIC LETTER

### Low hemodynamic impact of moderate ARDS caused by SARS-CoV2



### El SDRA moderado causado por el SARS-CoV2 tiene un bajo impacto hemodinámico

It has been proposed that SARS CoV2 patients who require invasive mechanical ventilation (MV) might represent a particular type of ARDS with a different ventilatory profile. On the other hand, they may also present with a distinct physiopathology element, consisting of a blunted hypoxic pulmonary vasoconstriction (HPV).<sup>1</sup>

Two SARS-Cov2 ARDS phenotypes have been described by Gattinoni et al. The majority of these patients represent Type L, characterized by higher compliance, and for which lower pressure ventilation is recommended because they don't have an extensive recruitable area and higher PEEP levels could negatively impact the right ventricle (RV).<sup>2</sup> Therefore, we might expect a specific hemodynamic profile, with less prevalence of RV failure. Hemodynamic profile of COVID-19 patients based on echocardiographic features have been previously described.<sup>3,4</sup>

The main objective of our study was to describe how MV (FiO<sub>2</sub> and PEEP) in patients with ARDS caused by SARS-CoV2 affects hemodynamics. Hemodynamic response was evaluated by conventional monitoring (invasive blood pressure monitoring) as well as echocardiography.

During the first and second wave of the COVID-19 pandemic we performed a single-centre, prospective, observational study, which included consecutive patients with a diagnosis of ARDS caused by SARS-CoV2 who required treatment with invasive MV. Inclusion criteria stated that patients were >18 y.o, had no previous cardiac nor respiratory chronic condition and were in the first 72 h of MV. The patients were treated with a protective ventilatory strategy, following the ARDSnet ventilation approach.

Study variable were hemodynamic parameters, echocardiographic biventricular function and respiratory mechanics.

Two transthoracic echocardiograms separated by an interval of 30 min, were performed during the first 72 h after initiation of MV. All patients were managed with a low PEEP high FiO<sub>2</sub> strategy which was the ventilatory approach of our unit, to keep a SaO<sub>2</sub> > 90%. The first echocardiogram (baseline) was done with ventilatory parameters set by the attending physician, without any additional intervention. The second echocardiogram was performed after a period of 30 min, either increasing the PEEP 2–4 cmH<sub>2</sub>O if a FiO<sub>2</sub> > 60% was necessary to reach the SaO<sub>2</sub> goal or

increasing the FiO<sub>2</sub> to 100% if the SaO<sub>2</sub> goal were reached with a lower FiO<sub>2</sub>, observe the hemodynamic response. After this maneuver, the patient was treated with the baseline ventilator settings.

Previously to the realization of the echocardiogram, arterial blood gas analysis was performed.

We included 20 patients, with moderate ARDS (baseline PaO<sub>2</sub>/FiO<sub>2</sub> 162,69 ± 58.80). Respiratory and hemodynamic variables are shown in Table 1. Except for one patient who needed low dose norepinephrine support, all patients showed hemodynamic stability with a mean arterial pressure (MAP) of 84.52 ± 13.09.

We observed that in both groups, ventilatory changes did not have a significant effect on hemodynamics except for a trend to a decrease in pulmonary acceleration time in the PEEP group (115,67 ± 8,45 ms baseline vs 111,17 ± 15.91 ms, *P* = .47).

All patients had preserved both left and right ventricular ejection fraction. None of the patients developed RV failure.

In the PEEP group, the slight increase in PEEP worsened pulmonary compliance but this was not followed by a hemodynamic worsening.

Despite the low oxygenation levels, this cohort of patients with SARS CoV2 shows that MV caused a low impact on hemodynamics. We obtained two groups of patients in which we observe that despite the differences in oxygenation (ratio of arterial partial pressure of oxygen to fraction of inspired oxygen PaO<sub>2</sub>/FiO<sub>2</sub> (116,98 ± 34,10 in PEEP group vs 222,46 ± 88,96 in FiO<sub>2</sub> group, *P* = ,001) the hemodynamic behavior is similar. All patients except one showed hemodynamic stability and they all presented a preserved RV function.

Despite that the most frequently observed phenotype was Type L, our cohort consists entirely of patients with phenotype H. However, the patients in our study present low systemic hemodynamic compromise, low right and left ventricular impact because of the changes in MV (PEEP and FiO<sub>2</sub>). A possible explanation could be the described abolition of the HPV. This circumstance would avoid the increment in pulmonary vascular resistance and RV compromise, despite low alveolar O<sub>2</sub> pressure and collapse. Moreover, given the use of low PEEP in our patients, the creation of overdistension areas could be avoided, along with capillary collapse and RV overload. Given the low RV compromise, we would probably trigger low LV compromise due to septal interdependence, which would explain at least in part the low systemic compromise, at least in our series. Regarding the low impact of the changes in MV, this could be explained by 1) due to the lack of hypothetical HPV, there would be little vasoreactivity to the O<sub>2</sub> changes

**Table 1** Study variables are shown: conventional hemodynamics, ventilatory mechanics, arterial blood gas analysis and echocardiographic parameters. The two groups PEEP and FiO2 were created depending on the FiO2 requirements in order to maintain SaO2 > 90%, as described in the text. The first echocardiogram was performed with mechanical ventilation set by the attending physician. The second echocardiogram was performed after mechanical ventilation changes described in the text.

PEEP GROUP, N = 7					FIO2 GROUP, N = 13					
First echocardiogram	Second echocardiogram				Ttest	First echocardiogram		Second echocardiogram		Ttest
	Mean	SD	Mean	SD		Mean	SD	Mean	SD	
Conventional hemodynamics										
SAP (mmHg)	121	± 19	125	± 22	0,159	123	± 15	119	± 17	0,295
DAP (mmHg)	66	± 12	66,29	± 10	0,658	65	± 9	62	± 8	0,221
MAP (mmHg)	85	± 16	86	± 13	0,692	85	± 12	81	± 13	0,079
HR (bpm)	66	± 17	71	± 20	0,060	67	± 16	65	± 17	0,255
CVP (mmHg)	9	± 5	10	± 4	0,373	9	± 4	10	± 6	0,593
PPV	0,03	± 0,02	0,03	± 0,03	0,734	0,02	± 0,01	0,01	± 0,07	0,221
Ventilatory mechanics										
TV abs (ml)	356	± 39	357	± 39		370	± 51	370	± 51	
TV/PBW (ml/kg)	5,91	± 0,27	5,91	± 0,27		6,10	± 0,83	6,10	± 0,83	
Mean airway pressure (cmH2O)	145	± 3	19	± 2	0,003	14	± 2	15	± 5	0,513
PEEP (cmH2O)	10	± 2,	14	± 2	2,6768E-06	9	± 1	9	± 1	0,058
PPeak (cmH2O)	31	± 5	35	± 4	0,007	28	± 5	28	± 4	0,807
PPlat (cmH2O)	22	± 2	28	± 2	3,0943E-05	20	± 3	20	± 4	0,421
DP (cmH2O)	12	± 2	13	± 3	0,016	10	± 3	9	± 3	0,4100
Compliance (ml/cmH2O)	16	± 2	13	± 1	0,0001	19	± 4	20	± 5	0,399
Arterial blood gas analysis										
PaO2 (mmHg)	91	± 41	90	± 16	0,956	84	± 22	222	± 89	0,0001637
PaCO2 (mmHg)	57	± 10,54	63	± 16	0,057	50	± 10	50	± 11	0,8443175
pH	7,36	± 0,05	7,33	± 0,04	0,289	7,41	± 0,04	7,42	± 0,05	0,4020282
Hb (g/dl)	11	± 1	11	± 1		11	± 2	12	± 2	
SaO2 (%)	95	± 3	96	± 3	0,974	95	± 3	99	± 1	0,0005239
HCO3 (mmol/l)	31	± 7	33	± 9	0,698	31	± 5	31	± 4	0,4305722
Lactate (mmol/l)	1,50	± 0,63	1,40	± 0,54	0,066	1,53	± 0,41	1,43	± 0,25	0,2265263
PaO2/FiO2	123,	± 64	117	± 34	0,804	182	± 46	222	± 89	0,0903584
Echocardiographic parameters										
RVOT VTI (cm)	15,20	± 3,28	15,33	± 2,22	0,935	15,17	± 3,01	14,71	± 4,41	0,588
PVAT (ms)	115,67	± 8,45	111,17	± 15,92	0,479	113,17	± 20,99	122,08	± 23,31	0,437
Vena cava (mm)	20,57	± 9,03	19,57	± 5,32	0,636	18,69	± 3,22	20,15	± 3,93	0,213
E wave (cm/s)	56,71	± 13,06	53,71	± 14,33	0,287	60,42	± 18,17	59,38	± 14,95	0,957
A wave (cm/s)	62,14	± 20,09	61,00	± 19,03	0,670	55,58	± 18,32	53,54	± 19,73	0,828
e' wave (cm/s)	8,14	± 2,85	8,71	± 2,36	0,547	9,42	± 5,43	9,31	± 3,97	0,632
LVOT VTI (cm)	20,75	± 2,36	18,04	± 1,44	0,100	20,43	± 3,96	19,08	± 5,17	0,180
TAPSE (mm)	22,71	± 4,57	25,00	± 3,00	0,199	23,46	± 3,84	22,54	± 3,78	0,311
RVD	41,14	± 3,48	39,86	± 4,41	0,328	38,00	± 3,70	36,38	± 4,37	0,140
LVD	45,14	± 5,18	45,86	± 5,76	0,556	44,23	± 4,48	42,62	± 5,32	0,063
RVD/LVD	0,92	± 0,13	0,88	± 0,12	0,09631156	0,87	± 0,11	0,86	± 0,13	0,950

SAP - Systolic Arterial Pressure, DAP - Dyastolic Arterial Pressure, MAP - Mean Arterial Pressure, HR - Heart Rate, CVP - Central Venous Pressure, PPV - Pulse Pressure Variation, RA - right atrium PPlat - Plateau Pressure, PPeak - peak pressure, FiO2 - Fraction of inspired oxygen, PaO2 - Partial Pressure of Oxygen, PaCO2 - Partial Pressure of Carbon Dioxide, Hb - Hemoglobin, SaO2 - Oxygen Saturation, LVOT VTI - Left Ventricular Outflow Tract Velocity Time Integral, RVOT VTI - Right Ventricular Outflow Tract Velocity Time Integral, PVAT - Pulmonary Velocity Acceleration Time, TAPSE - Tricuspid Annular Plane Systolic Excursion, RVD - Right Ventricular Diameter, LVD - Left Ventricular Diameter, SD - standard deviation, DP - driving pressure, PBW - predicted body weight.

(there wouldn't be any vasoconstriction relief when increasing the FiO2) therefore no changes are observed in the FiO2 change group) although it is highly probable that the monitoring techniques we used are not sensitive enough to detect the changes. 2) In the PEEP change group although an

overdistention trend was observed, a possible explanation of the observed low hemodynamic impact could be precisely the low PEEP that was used, probably starting at low transpulmonary pressure and low end expiratory volumes. The increment in these two last variables, as a consequence

of PEEP increment, could have not resulted in an excessively unfavourable situation for the relation between the pulmonary volume and pulmonary vascular resistance.

Our study is concordant with the hemodynamic findings mentioned by Evrard et al.,<sup>4</sup> the size of the cohort being similar. However, in our sample, as mentioned, no patient showed ventricular dysfunction.

An increase in PEEP tended to worsen pulmonary mechanics but without an enormous impact in hemodynamics.

The main limitation of the study is the small sample size which does not allow to draw more generalized conclusions regarding the objective of our research. Another limitation of our study is that the hemodynamic monitoring did not include advanced techniques that are able to detect cardiovascular change with high sensitivity.

Our result regarding the impact of MV on hemodynamics may be relevant at the time of choosing the best management strategy for this kind of patients.

*In memoriam*

In memoriam of our dear friend, Juan Martinez-Milla MD, PhD, who will always belong to the heart of our team.

## References

- Gattinoni L, Coppola S, Cressoni M, Busana M, Rossi S, Chiumello D. Covid-19 does not lead to a "typical" Acute Respira-

tory Distress Syndrome. *Am J Respir Crit Care Med.* 2020; <http://dx.doi.org/10.1164/rccm.202003-0817LE>. Published online March 30.

- Gattinoni L, Chiumello D, Rossi S. COVID-19 pneumonia: ARDS or not? *Crit Care.* 2020;24:154.
- Capotosto L, Nguyen BL, Ciardi MR, Mastroianni C, Vitarelli A. Heart, COVID-19 and echocardiography. *Echocardiography.* 2020;37:1454–64.
- Evrard B, Goudelin M, Montmagnon N, Fedou AL, Lafon T, Vignon P. Cardiovascular phenotypes in ventilated patients with COVID-19 acute respiratory distress syndrome. *Crit Care.* 2020;24:236.

Ana-Maria Ioan<sup>a</sup>, Oscar Gonzalez-Lorenzo<sup>b</sup>, Andrea Kallmeyer Mayor<sup>b</sup>, César Pérez-Calvo<sup>a</sup>, Arnaldo Santos<sup>a,\*</sup>

<sup>a</sup> *Department of Intensive Care Medicine, Hospital Universitario Fundación Jiménez Díaz, Avda. Reyes Católicos, 2, 28040 Madrid, Spain*

<sup>b</sup> *Department of Cardiology, Hospital Universitario Fundación Jiménez Díaz, Avda. Reyes Católicos, 2, 28040 Madrid, Spain*

\* Corresponding author.

E-mail address: [asantos@fjd.es](mailto:asantos@fjd.es) (A. Santos).

<https://doi.org/10.1016/j.medin.2023.01.002>  
0210-5691/ © 2023 Elsevier España, S.L.U. and SEMICYUC. All rights reserved.

## Development of pectoral muscle atrophy in critically ill patients



## Desarrollo de atrofia de los músculos pectorales en pacientes críticos

*Dear Editor:*

Skeletal muscle wasting and weakness have proven to be important determinants of critically ill patients' outcome. Reduced skeletal muscle mass on intensive care unit (ICU) admission has been associated with increased mortality and disability after discharge.<sup>1–3</sup> Moreover, muscle wasting occurring during ICU stay has also been associated with adverse outcomes.<sup>4</sup> However, the development of muscle atrophy in critically ill patients is highly heterogeneous among different muscle types.<sup>5,6</sup> Pectoral muscle area (PMA) on ICU admission, determined by computed tomography (CT) scan, has been associated with mortality.<sup>1,7</sup> On the contrary, tomographic evolution of PMA and its impact on patients' outcomes has not been reported. Therefore, we aimed to determine if the evolutionary pattern of PMA after ICU admission was associated with patient survival. We hypothesized that PMA wasting would be greater in non-survivors.

Thirty mechanically ventilated patients admitted to the ICU of a University Hospital (Hospital de Clínicas, Montevideo) from February 2016 to April 2020 and requiring two chest CT scans were retrospectively included in the study. Median time from ICU admission to the first CT scan was 0 (0–1) days and 12 (9–15) days for the second one. PMA

measurement was performed as previously described from a single axial slice of the CT scan.<sup>1</sup> Muscles were manually shaded in the first axial slice above the superior aspect of the aortic branch using specific software (Weasis Medical Viewer) and PMA was computed in square centimeters as the aggregated area of right and left major and minor pectoral muscles (Supplementary Fig. 1). The study was approved by the institution's Research Ethics Committee.

Categorical variables are reported as absolute numbers (percentage) and were compared using Chi-square test or Fisher exact test. Continuous variables are expressed as mean  $\pm$  standard deviation if normally distributed, or median (25th–75th percentile) if not. PMA evolution was analyzed through Wilcoxon signed-rank test. Student *t*-test or Mann–Whitney *U* test were performed to compare variables between groups. The Spearman correlation test was used to analyze bivariate correlations. Kaplan–Meier curves and the log-rank test were applied to compare ICU mortality in patient groups stratified by PMA. A *P* value < 0.05 was considered statistically significant.

Patient's characteristics are summarized in [Table 1](#). Most patients were male (77%), median time on mechanical ventilation was 21 (13–32) days and ICU mortality was 40%. The vast majority (87%) presented a low nutritional risk as assessed by the modified NUTRIC score (mNUTRIC).<sup>8</sup> Median PMA on admission CT scan (PMA<sub>1</sub>) was 27.0 (20.5–34.8) cm<sup>2</sup>, and was inversely correlated with patients' age ( $r_s = -0.506$ ,  $P = 0.004$ ), mNUTRIC ( $r_s = -0.717$ ,  $P < 0.001$ ) and SAPS III ( $r_s = -0.657$ ,  $P < 0.001$ ; Supplementary Figure 2). Males had a higher PMA on admission than females (34.1 (20.5–35.4) cm<sup>2</sup> versus 21.5 (19.3–24.3) cm<sup>2</sup>,